Literature DB >> 2674301

Study of 39 documented relapses of multibacillary leprosy after treatment with rifampin.

J H Grosset1, C C Guelpa-Lauras, P Bobin, G Brucker, J L Cartel, M Constant-Desportes, B Flageul, M Frédéric, J C Guillaume, J Millan.   

Abstract

Among 39 strains of Mycobacterium leprae isolated from patients with multibacillary leprosy who relapsed after treatment with rifampin (RMP), 22 strains were resistant to RMP and 17 were susceptible. All of the RMP-resistant strains were recovered from patients who had been treated with more than 50 doses of RMP, usually given as monotherapy. RMP-susceptible strains were recovered from only six patients who had received more than 50 doses of RMP, and from 11 patients who had received no more than seven doses. The median time to relapse after the beginning of RMP therapy was 9 years (range 1-12 years) among the patients harboring RMP-resistant strains of M. leprae, and the median time to relapse after discontinuation of RMP treatment was 7 years (range 1-11 years) among the patients harboring RMP-susceptible strains. These data suggest that monotherapy with more than a few doses of RMP can be responsible for the emergence of RMP-resistant strains of M. leprae, thus emphasizing the need to employ RMP only in combination with other effective drugs in the chemotherapy of multibacillary leprosy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2674301

Source DB:  PubMed          Journal:  Int J Lepr Other Mycobact Dis        ISSN: 0148-916X


  15 in total

1.  Molecular drug susceptibility testing and genotyping of Mycobacterium leprae strains from South America.

Authors:  Pushpendra Singh; Philippe Busso; Alberto Paniz-Mondolfi; Nacarid Aranzazu; Marc Monot; Nadine Honore; Andrea de Faria Fernandes Belone; Marcos Virmond; Maria Esther Villarreal-Olaya; Carlos Rivas; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2011-03-28       Impact factor: 5.191

2.  High relapse rate among lepromatous leprosy patients treated with rifampin plus ofloxacin daily for 4 weeks.

Authors:  B Ji; P Jamet; S Sow; E G Perani; I Traore; J H Grosset
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

Review 3.  Advances and hurdles on the way toward a leprosy vaccine.

Authors:  Malcolm S Duthie; Thomas P Gillis; Steven G Reed
Journal:  Hum Vaccin       Date:  2011-11-01

4.  Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers.

Authors:  M S Duthie; M N Hay; E M Rada; J Convit; L Ito; L K M Oyafuso; M I P Manini; I M B Goulart; J Lobato; L R Goulart; D Carter; S G Reed
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-05       Impact factor: 3.267

5.  Genotyping of Mycobacterium leprae from Brazilian leprosy patients suggests the occurrence of reinfection or of bacterial population shift during disease relapse.

Authors:  Adalgiza da Silva Rocha; Alexandre Araujo Cunha Dos Santos; Patrícia Pignataro; José Augusto Nery; Antônio Basílio de Miranda; Diego Fonseca Soares; Amanda Nogueira Brum Fontes; Alice Miranda; Helen Ferreira; Neio Boéchat; Maria Eugênia Novisck Gallo; Euzenir Nunes Sarno; Maria Leide W De Oliveira; Philip Noel Suffys
Journal:  J Med Microbiol       Date:  2011-05-19       Impact factor: 2.472

Review 6.  The continuing challenges of leprosy.

Authors:  D M Scollard; L B Adams; T P Gillis; J L Krahenbuhl; R W Truman; D L Williams
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

Review 7.  Chemotherapy of lepromatous leprosy: recent developments and prospects for the future.

Authors:  R H Gelber
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

8.  Molecular basis of rifampin resistance in Mycobacterium leprae.

Authors:  N Honore; S T Cole
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

9.  Characterization of rifampin-resistance in pathogenic mycobacteria.

Authors:  D L Williams; C Waguespack; K Eisenach; J T Crawford; F Portaels; M Salfinger; C M Nolan; C Abe; V Sticht-Groh; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

10.  Detection of antibiotic resistance in leprosy using GenoType LepraeDR, a novel ready-to-use molecular test.

Authors:  Emmanuelle Cambau; Aurélie Chauffour-Nevejans; Liana Tejmar-Kolar; Masanori Matsuoka; Vincent Jarlier
Journal:  PLoS Negl Trop Dis       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.